Small Pharma’s (CVE:DMT) Carol Routledge, Chief Medical and Scientific Officer joins Proactive London’s Katie Pilbeam to discuss their specialism in psychedelics. Carol explains their key trial which is now in phase I/IIa based in the UK at Imperial College London.
The firm is now accelerating this trial, working with MAC, a leading CRO specialised in psychedelic-assisted studies.
The trial has been expanded to include 42 people and that the increased space will mean the topline results can be expected earlier than anticipated - in H1 next year.
The company recently listed on the TSVX stock exchange in Canada raising c$63 million, a vibrant market with a strong base of psychedelic drug companies.